rontalizumab

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 464383569

| type = mab

| mab_type = mab

| source = zu

| target = IFN-α

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 948570-30-7

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| KEGG = D09662

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = LDO2FIQ61I

| chemical_formula =

| C=6486 | H=9990 | N=1722 | O=2026 | S=44

}}

Rontalizumab is a humanized monoclonal antibody[https://www.who.int/medicines/publications/druginformation/innlists/PLFinal101.pdf WHO Drug Information] being developed by Genentech.[http://www.gene.com/gene/pipeline/status/immunology/rhumab-ifnalpha/ Genentech: Rontalizumab (rhuMAb IFN alpha)] {{as of|2009|11}}, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.{{ClinicalTrialsGov|NCT00962832|A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)}}{{cite journal | vauthors = Misra DP, Negi VS | title = Interferon targeted therapies in systemic lupus erythematosus | journal = Mediterranean Journal of Rheumatology | volume = 28 | issue = 1 | pages = 13–19 | date = March 2017 | pmid = 32185249 | pmc = 7045923 | doi = 10.31138/mjr.28.1.13 }}